Disease Clusters?
Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.
← Back to all clusters
Cluster 328
6
Diseases
8
Unique genes
0.298
Avg. similarity score
Atrioventricular excitation abnormality
Most-connected disease (5 links)
Disease
Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details ·
click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) ·
drag a node to pin it in place · scroll/pinch to zoom.
Atrioventricular excitation abnormality
Keppen-lubinsky syndrome
MYH-6 related congenital heart defects
dilated cardiomyopathy 1EE
Bile duct disorder
PRKAG2-related cardiomyopathy
Member diseases (most connected first ‐ the cluster's core)
| Disease ⇵ | Connections in cluster ⇵ | Significant partners ⇵ | Curated genes ⇵ |
|---|---|---|---|
| Atrioventricular excitation abnormality | 5 | 5 | 2 |
| Keppen-lubinsky syndrome | 3 | 3 | 2 |
| MYH-6 related congenital heart defects | 3 | 3 | 1 |
| dilated cardiomyopathy 1EE | 3 | 3 | 1 |
| Bile duct disorder | 2 | 2 | 6 |
| PRKAG2-related cardiomyopathy | 2 | 2 | 1 |
Top shared genes (genes linked to 2+ member diseases)
| Gene ⇵ | Member diseases ⇵ | Linked diseases |
|---|---|---|
| MYH6 | 4 / 6 | Atrioventricular excitation abnormality, dilated cardiomyopathy 1EE, Keppen-lubinsky syndrome, MYH-6 related congenital heart defects |
| PRKAG2 | 3 / 6 | Atrioventricular excitation abnormality, Bile duct disorder, PRKAG2-related cardiomyopathy |
What do these columns mean?
- Connections in cluster
- How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
- Significant partners
- How many of those links are statistically significant (FDR q < 0.05).
- Curated genes
- Distinct curated genes linked to that disease in GeDiPNet.
- Member diseases (Top shared genes)
- How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
- Overlap genes (x / y)
- x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
- Cluster gene count
- Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
- Fold enrichment
- Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
- P-value / FDR q-value
- Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
- Shared genes (Pairs within this cluster)
- Number of curated genes the two diseases in that row have in common.
- Similarity score (Pairs within this cluster)
- Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.
Enriched Pathways (why this cluster is grouped, biologically)
| Pathway ⇵ | Source ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Oxytocin signaling pathway | KEGG | 3 / 154 | 29.2× | 1.10e-4 | 2.43e-3 ✓ sig. |
| Longevity regulating pathway - multiple species | KEGG | 2 / 62 | 48.4× | 7.20e-4 | 1.06e-2 ✓ sig. |
| GABAergic synapse | KEGG | 2 / 89 | 33.7× | 1.48e-3 | 1.83e-2 ✓ sig. |
| Longevity regulating pathway | KEGG | 2 / 90 | 33.4× | 1.51e-3 | 1.86e-2 ✓ sig. |
| Morphine addiction | KEGG | 2 / 91 | 33.0× | 1.54e-3 | 1.89e-2 ✓ sig. |
| Circadian entrainment | KEGG | 2 / 97 | 31.0× | 1.75e-3 | 2.07e-2 ✓ sig. |
| Hypertrophic cardiomyopathy | KEGG | 2 / 99 | 30.3× | 1.82e-3 | 2.14e-2 ✓ sig. |
| Dilated cardiomyopathy | KEGG | 2 / 105 | 28.6× | 2.05e-3 | 2.32e-2 ✓ sig. |
| Progesterone-mediated oocyte maturation | KEGG | 2 / 110 | 27.3× | 2.25e-3 | 2.48e-2 ✓ sig. |
| Cholinergic synapse | KEGG | 2 / 115 | 26.1× | 2.45e-3 | 2.65e-2 ✓ sig. |
| G2/M DNA replication checkpoint | Reactome | 1 / 5 | 300× | 3.33e-3 | 3.31e-2 ✓ sig. |
| Oocyte meiosis | KEGG | 2 / 138 | 21.8× | 3.51e-3 | 3.43e-2 ✓ sig. |
| Estrogen signaling pathway | KEGG | 2 / 139 | 21.6× | 3.56e-3 | 3.47e-2 ✓ sig. |
| Apelin signaling pathway | KEGG | 2 / 140 | 21.4× | 3.61e-3 | 3.50e-2 ✓ sig. |
| AMPK inhibits chREBP transcriptional activation activity | Reactome | 1 / 6 | 250× | 3.99e-3 | 3.77e-2 ✓ sig. |
Enriched GO Terms (Biological Process, a second line of biological evidence)
| GO term ⇵ | GO ID ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| visceral muscle development | GO:0007522 | 1 / 1 | 2,336× | 4.28e-4 | 8.59e-3 ✓ sig. |
| regulation of heart growth | GO:0060420 | 1 / 2 | 1,168× | 8.56e-4 | 1.36e-2 ✓ sig. |
| negative regulation of G2/MI transition of meiotic cell cycle | GO:0110031 | 1 / 3 | 779× | 1.28e-3 | 1.75e-2 ✓ sig. |
| regulation of carbon utilization | GO:0043609 | 1 / 3 | 779× | 1.28e-3 | 1.75e-2 ✓ sig. |
| oocyte differentiation | GO:0009994 | 1 / 4 | 584× | 1.71e-3 | 2.07e-2 ✓ sig. |
| muscle system process | GO:0003012 | 1 / 5 | 467× | 2.14e-3 | 2.34e-2 ✓ sig. |
| regulation of fatty acid oxidation | GO:0046320 | 1 / 5 | 467× | 2.14e-3 | 2.34e-2 ✓ sig. |
| positive regulation of DNA metabolic process | GO:0051054 | 1 / 6 | 389× | 2.57e-3 | 2.58e-2 ✓ sig. |
| positive regulation of meiotic nuclear division | GO:0045836 | 1 / 6 | 389× | 2.57e-3 | 2.58e-2 ✓ sig. |
| positive regulation of transcription of Notch receptor target | GO:0007221 | 1 / 7 | 334× | 2.99e-3 | 2.82e-2 ✓ sig. |
| atrial cardiac muscle tissue morphogenesis | GO:0055009 | 1 / 7 | 334× | 2.99e-3 | 2.82e-2 ✓ sig. |
| regulation of D-glucose import | GO:0046324 | 1 / 8 | 292× | 3.42e-3 | 3.03e-2 ✓ sig. |
| regulation of fatty acid metabolic process | GO:0019217 | 1 / 11 | 212× | 4.70e-3 | 3.56e-2 ✓ sig. |
| cAMP biosynthetic process | GO:0006171 | 1 / 11 | 212× | 4.70e-3 | 3.56e-2 ✓ sig. |
| in utero embryonic development | GO:0001701 | 2 / 252 | 18.5× | 4.81e-3 | 3.58e-2 ✓ sig. |
Pairs within this cluster, by significance
| Disease A ⇵ | Disease B ⇵ | Similarity score ⇵ | Shared genes ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| dilated cardiomyopathy 1EE | MYH-6 related congenital heart defects | 0.500 | 1 | 6.49e-5 | 2.34e-4 ✓ sig. |
| Atrioventricular excitation abnormality | PRKAG2-related cardiomyopathy | 0.333 | 1 | 1.30e-4 | 3.90e-4 ✓ sig. |
| Atrioventricular excitation abnormality | MYH-6 related congenital heart defects | 0.333 | 1 | 1.30e-4 | 3.90e-4 ✓ sig. |
| Atrioventricular excitation abnormality | dilated cardiomyopathy 1EE | 0.333 | 1 | 1.30e-4 | 3.90e-4 ✓ sig. |
| dilated cardiomyopathy 1EE | Keppen-lubinsky syndrome | 0.333 | 1 | 1.30e-4 | 3.90e-4 ✓ sig. |
| Keppen-lubinsky syndrome | MYH-6 related congenital heart defects | 0.333 | 1 | 1.30e-4 | 3.90e-4 ✓ sig. |
| Atrioventricular excitation abnormality | Keppen-lubinsky syndrome | 0.250 | 1 | 2.60e-4 | 6.40e-4 ✓ sig. |
| Bile duct disorder | PRKAG2-related cardiomyopathy | 0.143 | 1 | 3.90e-4 | 8.52e-4 ✓ sig. |
| Atrioventricular excitation abnormality | Bile duct disorder | 0.125 | 1 | 7.79e-4 | 1.39e-3 ✓ sig. |